德国转移性前列腺癌二十年真实世界总生存趋势
基于德国国家癌症登记1999–2021年54,890例初诊转移性前列腺癌(M1)患者,中位总生存从1999年31.0个月改善至2019年37.0个月(p<0.001)。年龄分层显示<70岁患者从34.0个月增至49.0个月(+44.1%),≥70岁患者仅从28.0个月增至29.0个月(+3.6%)。
要点
- 德国M1前列腺癌中位OS二十年改善19.4%,年轻患者获益显著
- ≥70岁患者OS改善有限(28.0→29.0个月),提示治疗不足可能
- 诊断年份为OS独立预测因素(HR 0.96,95%CI 0.96–0.97)
核心结论
- 真实世界数据证实转移性前列腺癌二十年生存改善,验证了临床试验疗效向常规实践的转化。
- 年龄相关差异显著,提示老年患者可能存在治疗不足,需年龄适配治疗策略。
研究设计与样本
- 基于德国国家癌症登记1999–2021年657,499例前列腺癌病例,排除后纳入54,890例初诊转移性(M1)患者。
- 主要结局为中位总生存(OS),次要结局包括3年、5年、10年生存率。
- 采用增广Dickey-Fuller检验和joinpoint回归进行时间趋势分析。
主要发现
- M1患者中位OS从1999年31.0个月(95%CI 29.8–32.2)改善至2019年37.0个月(95%CI 35.6–38.4),p<0.001,改善19.4%。
- <70岁患者中位OS从34.0个月增至49.0个月(+44.1%),≥70岁患者从28.0个月增至29.0个月(+3.6%)。
- 3年生存率从45.1%增至50.9%(p=0.004);2019年年轻患者3年生存率61.3%,老年患者44.0%。
- 多因素Cox回归确认诊断年份为独立预测因素(HR 0.96,95%CI 0.96–0.97,p<0.001)。
临床怎么用
- 真实世界数据支持新型内分泌药物、化疗联合、PARP抑制剂及放射配体治疗在转移性前列腺癌中的临床获益。
- 对老年转移性前列腺癌患者应评估治疗不足风险,考虑年龄适配的治疗策略。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: The management of metastatic prostate cancer (mPCa) has undergone revolutionary changes over the past two decades with the introduction of novel hormonal agents, chemotherapy combinations, PARP inhibitors, and radioligand therapies. This study evaluates the real-world impact of these therapeutic advances on overall survival (OS) in Germany. METHODS: We analyzed data from the German national cancer registry covering 657,499 prostate cancer cases diagnosed between 1999 and 2021. After exclusions, 54,890 patients with de novo metastatic disease (M1) were included. Primary outcome was median OS. Secondary outcomes included 3-, 5-, and 10-year survival rates. Time series analysis assessed temporal trends using augmented Dickey-Fuller tests and joinpoint regression. RESULTS: Median OS for M1 patients improved from 31.0 months (95% CI: 29.8-32.2) in 1999 to 37.0 months (35.6-38.4) in 2019 (p < 0.001). This 19.4% improvement exceeded general life expectancy gains. Age-stratified analysis revealed disparate benefits: patients < 70 years experienced improvement from 34.0 to 49.0 months ( + 44.1%), while those ≥ 70 years showed minimal change (28.0 to 29.0 months, +3.6%). Three-year survival increased from 45.1% to 50.9% (p = 0.004), with younger patients achieving 61.3% versus 44.0% for older patients by 2019. Multivariate Cox regression confirmed diagnosis year as an independent predictor (HR 0.96, 95% CI: 0.96-0.97, p < 0.001). CONCLUSIONS: Real-world data confirm meaningful survival improvements in metastatic prostate cancer over two decades, validating the translation of clinical trial efficacy into routine practice. However, the pronounced age-related disparity suggests potential undertreatment of elderly patients and highlights the need for age-adapted treatment strategies.
引用
- Sondermann M, Stehr A, Hirtsiefer C, et al. Survival trend in metastatic prostate cancer two decades of real-world data on overall survival from Germany. Prostate Cancer Prostatic Dis. 2026. PMID: 41735525. doi:10.1038/s41391-026-01092-w
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。